Anebulo Pharmaceuticals, Inc.
Data quality: 83%
ANEB
OTC
Manufacturing
Chemicals
$0.60
▼
$0.05
(-7.82%)
Mkt Cap: 24.51 M
Price
$0.60
Mkt Cap
24.51 M
Day Range
$0.58 — $0.58
52-Week Range
$0.30 — $3.42
Volume
2,460
Open $0.58
50D / 200D Avg
$0.70
13.56% below
50D / 200D Avg
$1.79
66.52% below
Quick Summary
Key Takeaways
Negative free cash flow of -5.84 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-90.29%
Below sector avg (-53.41%)
ROIC-71.48%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current RatioN/A
Interest Coverage-28.84
Valuation
PE (TTM)
-3.07
Below sector avg (-1.48)
P/B Ratio3.09
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -3.1 | -1.5 |
| P/B | 3.1 | 1.6 |
| ROE % | -90.3 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -7.98 M |
| ROE | -90.29% | ROA | -79.30% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -5.84 M |
| ROIC | -71.48% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | -28.84 | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | 7.94 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3.07 | Forward P/E | N/A |
| P/B Ratio | 3.09 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -23.83% | ||
| Market Cap | 24.51 M | Enterprise Value | 15.47 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.18 | Revenue / Share | N/A |
| FCF / Share | -0.14 | OCF / Share | -0.14 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 73.20% |
| SBC-Adj. FCF | -6.82 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -8.48 M | -8.20 M | -11.73 M | -30.25 M | -6.83 M |
| EPS (Diluted) | -0.25 | -0.32 | 0.47 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -9.22 M | -8.31 M | -11.78 M | — | -6.83 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 4.30 M | 3.55 M | 5.60 M | 2.27 M | 2.96 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 400,000.0 | 151,230.0 | — | 11,767.0 | 11,767.0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Total Assets | 12.15 M | 4.07 M | 11.67 M | 21.65 M | 15.58 M |
| Total Liabilities | 487,688.0 | 260,583.0 | 1.07 M | 241,633.0 | 512,531.0 |
| Shareholders' Equity | 11.66 M | 3.81 M | 10.60 M | 21.41 M | 15.07 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 11.63 M | 3.09 M | — | — | — |
| Current Assets | 11.96 M | 3.51 M | — | — | — |
| Current Liabilities | — | — | — | — | — |
{"event":"ticker_viewed","properties":{"ticker":"ANEB","listing_kind":"stock","pathname":"/stocks/aneb","exchange":"OTC","country":"US"}}